Driving the future of health

Meet 11 early-stage founders currently scaling their innovations

Research Grid founder and CEO Dr Amber Hill is one of 11 EMEA-based founders to be selected for the latest cohort of Morgan Stanley’s Inclusive Ventures Lab.

Inclusive Ventures Lab: 2024 Cohort | Morgan Stanley

Research Grid was one of 25 startups chosen globally for Morgan Stanley’s in-house accelerator.

The Business Growth Superpower

Our CEO Dr Amber Hill shares her insights on how AI-driven approaches to data management can deliver sustainable top-line growth in clinical research.

AI-driven clinical trials: The full potential of AI in drug development

AI is rapidly advancing drug discovery. However, the focus is shifting towards the next frontier: AI-driven clinical trials. R.grid’s solutions are one way that researchers can incorporate AI into their workflow to make their trials faster and more successful.

From the Lab to Life: 5 Major Developments in Clinical Trials and Community Engagement

In recent months, there have been major events in the UK, Europe, and the US that are reshaping clinical trials and community engagement. The contributions of companies like Research Grid will be crucial in achieving the goals set forth in these recent developments.

AI Cancer Care Solutions Changing Prevention and Treatment Strategies

R.grid's SaaS research platforms can serve as a powerful tool in optimizing and streamlining clinical trials, enhancing efficiency and providing better patient outcomes.

We use some essential cookies to make this service work. We’d also like to use analytics cookies so we can understand how you use the service and make improvements. If you agree to the use of all functional cookies, click “Accept Cookies”. If you wish to only allow the use of essential cookies, click “Reject Cookies”. For more information, read our Cookie Policy here.